We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Ariel Cruz Figueroa
Ariel Cruz Figueroa
Products
PRODUCTS
Kingkey MBC Life Technology Group Co., Ltd.
Ariel Cruz Figueroa
Price:
$117.00
View
Neolpharma, Inc.
Ariel Cruz Figueroa
Price:
$117.00
View
Akorn AG
Ariel Cruz Figueroa
and
Jason K. Morgan
Price:
$117.00
View
Star Lake Bioscience Co., Inc.
Ariel Cruz Figueroa
Price:
$117.00
View
Unichem Laboratories, Ltd.
Ariel Cruz Figueroa
Price:
$117.00
View
Mylan Laboratories Ltd.
Ariel Cruz Figueroa
Price:
$117.00
View
Morton Drug Co. dba Morton LTC
Ariel Cruz Figueroa
and
Liming Zhang
Price:
$117.00
View
Pacific Healthcare, Inc. dba B&B Pharmacy
Ariel Cruz Figueroa
and
Binh T. Nguyen
Price:
$117.00
View
Galephar Pharmaceutical Research, Inc.
Ariel Cruz Figueroa
and
German Rivera
Price:
$117.00
View
Warner Chilcott Company, LLC
Cassandra L. Abellard
,
Ariel Cruz Figueroa
, and
Jose E. Melendez
Price:
$117.00
View
View All Products by Ariel Cruz Figueroa
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More